LGND LIGAND PHARMACEUTICALS INC
Q3 2025 10-Q
LIGAND PHARMACEUTICALS INC (LGND) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New risk: Convertible Senior Notes $460M offering in Aug 2025 adds debt with 0.75% coupon due 2030, introducing dilution and interest expense risks
- • Updated operational risk: Pelthos merger and divestiture yielding $53.1M income changes revenue profile and partnership dynamics notably in Q3 2025
Quarterly Financial SummaryXBRL
Revenue
$115M
▲ +122.8% YoY▲ +142.4% QoQ
Net Income
$117M
▲ +1735.2% YoY▲ +2319.5% QoQ
Operating Margin
47.6%
▲ +4151bp YoY▲ +2985bp QoQ
Net Margin
101.6%
▲ +11541bp YoY▲ +9139bp QoQ
ROE
12.3%
Total Assets
$1.5B
EPS (Diluted)
$5.90
▲ +1539.0% YoY▲ +2169.2% QoQ
Operating Cash Flow
$13M
▼ -64.2% YoY▼ -17.1% QoQ
Source: XBRL data from LIGAND PHARMACEUTICALS INC Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on LIGAND PHARMACEUTICALS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.